HZL 105
Alternative Names: HZ-L105Latest Information Update: 26 Feb 2023
At a glance
- Originator Hangzhou HealZen Therapeutics
- Class Antineoplastics
- Mechanism of Action Proto-oncogene protein c-bcl-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies
Most Recent Events
- 10 Dec 2022 Preclinical trials in Haematological malignancies in China (PO), before December 2022
- 10 Dec 2022 Pharmacodynamics, pharmacokinetics and adverse events data from preclinical studies in Haematological malignancies presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)
- 27 Oct 2021 Hangzhou HealZen Therapeutics files for patent protection for HZ L105 in China